ADMA Biologics, Inc. (NasdaqGM: ADMA)
Health Care · Biotechnology · US
$9.72
+1.78% today · -42.9% 1Y
ADMA Biologics, Inc. (NasdaqGM: ADMA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.18B and employs 644 people.
Over the last twelve months the share price has lost 42.9%, trading between 7.21 and 20.46.
Tweenvest scores ADMA Biologics, Inc. across four factors: quality 72/100, value 63/100, growth 100/100. Its strongest factor is growth.
ADMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.18B
- Revenue (TTM)
- $512.27M
- P/E
- 13.88
- EPS
- 0.70
- Dividend yield
- —
- Beta (5Y)
- 0.77
- 52-week high
- $20.46
- 52-week low
- $7.21
- Avg volume (3M)
- —
- Shares outstanding
- 223.98M
- Employees
- 644
- Next earnings
- —
About ADMA Biologics, Inc.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
- ISIN
- US0008991046
- Founded
- 2004
- Listed since
- Oct 17, 2013
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.